Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) (EGX:RMDA)
Egypt
· Delayed Price · Currency is EGP 4.550
-0.060 (-1.30%)
At close: Apr 28, 2026
EGX:RMDA Ratios and Metrics
Market cap in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Market Capitalization | 9,100 | 6,660 | 5,022 | 2,459 | 2,892 | 2,400 | Upgrade
|
| Market Cap Growth | 38.82% | 32.63% | 104.18% | -14.96% | 20.51% | -18.04% | Upgrade
|
| Enterprise Value | 11,514 | 8,919 | 5,881 | 3,259 | 3,284 | 3,006 | Upgrade
|
| Last Close Price | 4.55 | 3.33 | 2.46 | 1.18 | 1.40 | 1.12 | Upgrade
|
| PE Ratio | 34.06 | 24.79 | 13.80 | 11.00 | 12.63 | 14.42 | Upgrade
|
| Forward PE | 16.45 | 9.19 | 10.84 | 7.72 | 9.25 | 10.10 | Upgrade
|
| PS Ratio | 2.22 | 1.63 | 1.81 | 1.28 | 1.95 | 1.93 | Upgrade
|
| PB Ratio | 4.12 | 3.01 | 2.42 | 1.39 | 1.90 | 1.78 | Upgrade
|
| P/TBV Ratio | 8.61 | 6.30 | 3.37 | 2.10 | 2.73 | 2.50 | Upgrade
|
| P/FCF Ratio | - | - | - | - | - | 12.72 | Upgrade
|
| P/OCF Ratio | - | - | - | - | 98.55 | 9.94 | Upgrade
|
| PEG Ratio | 0.54 | 0.28 | 0.28 | 0.28 | 0.28 | 0.27 | Upgrade
|
| EV/Sales Ratio | 2.81 | 2.18 | 2.12 | 1.70 | 2.21 | 2.41 | Upgrade
|
| EV/EBITDA Ratio | 10.92 | 8.53 | 7.31 | 6.33 | 8.14 | 9.49 | Upgrade
|
| EV/EBIT Ratio | 11.96 | 9.27 | 8.11 | 7.31 | 9.60 | 10.96 | Upgrade
|
| EV/FCF Ratio | -57.70 | - | - | - | - | 15.93 | Upgrade
|
| Debt / Equity Ratio | 1.09 | 1.09 | 0.76 | 0.63 | 0.61 | 0.65 | Upgrade
|
| Debt / EBITDA Ratio | 2.28 | 2.28 | 1.94 | 2.15 | 2.28 | 2.75 | Upgrade
|
| Debt / FCF Ratio | - | - | - | - | - | 4.66 | Upgrade
|
| Net Debt / Equity Ratio | 1.07 | 1.07 | 0.63 | 0.45 | 0.33 | 0.30 | Upgrade
|
| Net Debt / EBITDA Ratio | 2.27 | 2.27 | 1.63 | 1.56 | 1.24 | 1.26 | Upgrade
|
| Net Debt / FCF Ratio | -11.89 | -11.89 | -3.53 | -5.91 | -99.72 | 2.11 | Upgrade
|
| Asset Turnover | 0.85 | 0.85 | 0.74 | 0.64 | 0.57 | 0.53 | Upgrade
|
| Inventory Turnover | 2.37 | 2.37 | 2.82 | 3.13 | 2.52 | 2.37 | Upgrade
|
| Quick Ratio | 0.38 | 0.38 | 0.53 | 0.54 | 0.62 | 0.76 | Upgrade
|
| Current Ratio | 1.15 | 1.15 | 1.46 | 1.47 | 1.49 | 1.44 | Upgrade
|
| Return on Equity (ROE) | 14.63% | 14.63% | 20.89% | 15.35% | 17.63% | 14.24% | Upgrade
|
| Return on Assets (ROA) | 12.47% | 12.47% | 12.04% | 9.30% | 8.24% | 7.34% | Upgrade
|
| Return on Invested Capital (ROIC) | 15.86% | 17.85% | 18.59% | 14.98% | 13.99% | 12.53% | Upgrade
|
| Return on Capital Employed (ROCE) | 40.90% | 40.90% | 33.60% | 24.20% | 21.50% | 19.60% | Upgrade
|
| Earnings Yield | 2.95% | 4.48% | 7.71% | 9.96% | 8.49% | 7.54% | Upgrade
|
| FCF Yield | -2.19% | -3.00% | -7.41% | -5.51% | -0.17% | 7.86% | Upgrade
|
| Dividend Yield | 0.87% | - | 1.63% | 4.29% | - | - | Upgrade
|
| Payout Ratio | 63.29% | 63.30% | 31.31% | 6.85% | 9.89% | 8.12% | Upgrade
|
| Buyback Yield / Dilution | -0.02% | -0.02% | -1.11% | -1.27% | 2.62% | - | Upgrade
|
| Total Shareholder Return | 0.85% | -0.02% | 0.52% | 3.02% | 2.62% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.